Philip Kantoff
Medical Oncology
Credentials: · · ·
History
- 1983–1985
Medical Oncology
Research
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
New England Journal of Medicine · 2010 · First of 14 authors · Corresponding · 4,436 citations
Cancer nanomedicine: progress, challenges and opportunities
Review · Nature reviews. Cancer · 2017 · 3,904 citations
Integrative clinical genomics of advanced prostate cancer
Cell · 2015 · 2,800 citations
- WO
82 papers
59 papers
49 papers
43 papers
42 papers · 5 as a fellow
40 papers
40 papers
38 papers · 2 as a resident
Grants
- 2019–2026
The Impact of DNA Damage Repair Abnormalities in Prostate Cancer
National Cancer Institute · P01
Contact PI · $2.3M · Sloan-Kettering Inst Can Research
- 2016–2020
National Cancer Institute · U01
Contact PI · $1.3M · Sloan-Kettering Inst Can Research
- 2001–2019
DF/HCC SPORE in Prostate Cancer
National Cancer Institute · P50
Contact PI · $31.4M · Dana-Farber Cancer Inst
- 2016
Dana-Farber/Harvard Cancer Center
National Cancer Institute · P30
Project lead · $453.6K · Dana-Farber Cancer Inst
Clinical trials
- 2011–2017
Principal investigator · Completed · Phase 3
Bavarian Nordic
- 2009
Principal investigator · Unknown
Source MDx
- 2002–2006
Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
Principal investigator · Completed · Phase 2, Phase 3
Dana-Farber Cancer Institute